Medicare Enrolled
Dr. Shailja Roy, MD
Hematology & Oncology · Vineland, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Roy from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Roy?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Roy
Dr. Shailja Roy is a hematology & oncology specialist in Vineland, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Roy performed 106,520 Medicare services across 2,199 unique beneficiaries.
Between the years covered by Open Payments, Dr. Roy received a total of $6,401 from 75 pharmaceutical and/or device companies across 386 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Roy is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 8% volume in NJ
$6,401 industry payments
Medicare Practice Summary
Medicare Utilization ↗106,520
Medicare services
Top 8% in NJ for hematology & oncology
2,199
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~5,326 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
60,000 | $1 | $3 |
| Pembrolizumab injection (Keytruda) | 9,400 | $43 | $65 |
| Denosumab injection (Prolia/Xgeva) | 7,140 | $19 | $50 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
7,000 | $0 | $1 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
6,900 | $0 | $3 |
| Eflapegrastim injection, 0.1 mg An injection of eflapegrastim-xnst administered at a dose of 0.1 mg. |
4,224 | $25 | $100 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,569 | $0 | $1 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
1,440 | $6 | $50 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,070 | $1 | $50 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,041 | $8 | $30 |
| Anti-nausea injection (ondansetron/Zofran) | 1,028 | $0 | $2 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
960 | $6 | $25 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
507 | $71 | $150 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
439 | $106 | $200 |
| Injection, leucovorin calcium, per 50 mg | 419 | $3 | $15 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
390 | $14 | $76 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
315 | $12 | $80 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
289 | $118 | $300 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
254 | $2 | $20 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
247 | $2 | $100 |
| Pegfilgrastim-cbqv injection An injection of pegfilgrastim-cbqv, a biosimilar medication, administered at a dose of 0.5 mg. |
240 | $106 | $700 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
190 | $26 | $96 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
127 | $56 | $200 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
124 | $147 | $299 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
121 | $67 | $156 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
112 | $25 | $200 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
104 | $1 | $10 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
101 | $11 | $100 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
99 | $66 | $150 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
94 | $58 | $150 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
90 | $147 | $373 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
85 | $1 | $10 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
84 | $1 | $13 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
52 | $50 | $250 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
50 | $18 | $95 |
| New patient office visit, complex (60-74 min) | 44 | $176 | $400 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
40 | $27 | $200 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
37 | $10 | $25 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
32 | $101 | $207 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
28 | $42 | $76 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
18 | $138 | $300 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
16 | $22 | $75 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
57.1% high complexity
40.4% medium
2.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,401
Total received (2018-2024)
Avg $914/year across 7 years
Top 37% in NJ for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
75
Companies
386
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,386 (99.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$15 (0.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,649
2023
$1,728
2022
$1,027
2021
$333
2020
$192
2019
$836
2018
$636
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$239
AstraZeneca Pharmaceuticals LP
$114
GlaxoSmithKline, LLC.
$85
E.R. Squibb & Sons, L.L.C.
$85
Merck Sharp & Dohme LLC
$72
Eisai Inc.
$68
Novartis Pharmaceuticals Corporation
$66
Celgene Corporation
$65
Lilly USA, LLC
$65
Daiichi Sankyo Inc.
$62
ABBVIE INC.
$61
Karyopharm Therapeutics Inc.
$55
Incyte Corporation
$44
Alexion Pharmaceuticals, Inc.
$39
Stemline Therapeutics Inc.
$34
BeiGene USA, Inc.
$32
Gilead Sciences, Inc.
$32
Spectrum Pharmaceuticals Inc.
$24
Takeda Pharmaceuticals U.S.A., Inc.
$21
Genentech USA, Inc.
$21
ADC Therapeutics America, Inc.
$21
Bayer Healthcare Pharmaceuticals Inc.
$20
Kite Pharma, Inc.
$20
Agios Pharmaceuticals, Inc.
$19
Genmab U.S., Inc.
$19
Deciphera Pharmaceuticals Inc.
$18
Tempus AI, Inc
$18
Geron Corporation
$18
SERVIER PHARMACEUTICALS LLC
$17
Janssen Pharmaceuticals, Inc
$17
SOBI, INC
$16
EMD Serono, Inc.
$16
GENZYME CORPORATION
$16
ARRAY BIOPHARMA INC
$16
Janssen Biotech, Inc.
$16
PUMA BIOTECHNOLOGY, INC.
$15
Celltrion USA Inc.
$14
Astellas Pharma US Inc
$14
Exelixis Inc.
$14
Apellis Pharmaceuticals, Inc.
$14
Acrotech Biopharma Inc.
$14
Rigel Pharmaceuticals, Inc.
$13
Top 3 companies account for 26.5% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$528
PFIZER INC.
$508
Genentech USA, Inc.
$420
AstraZeneca Pharmaceuticals LP
$292
Celltrion USA Inc.
$246
E.R. Squibb & Sons, L.L.C.
$243
Merck Sharp & Dohme LLC
$238
Janssen Biotech, Inc.
$228
Celgene Corporation
$173
GlaxoSmithKline, LLC.
$158
Pharmacyclics LLC, An AbbVie Company
$150
Astellas Pharma US Inc
$144
Exelixis Inc.
$130
Bayer HealthCare Pharmaceuticals Inc.
$126
Lilly USA, LLC
$123
GENZYME CORPORATION
$123
Seagen Inc.
$122
Incyte Corporation
$118
Gilead Sciences, Inc.
$114
Eisai Inc.
$111
Daiichi Sankyo Inc.
$105
TESARO, Inc.
$101
ABBVIE INC.
$87
BeiGene USA, Inc.
$87
EMD Serono, Inc.
$86
Janssen Pharmaceuticals, Inc
$86
Spectrum Pharmaceuticals Inc.
$81
Apellis Pharmaceuticals, Inc.
$80
Karyopharm Therapeutics Inc.
$77
Merck Sharp & Dohme Corporation
$69
Kite Pharma, Inc.
$68
AbbVie, Inc.
$64
Alexion Pharmaceuticals, Inc.
$62
Amgen Inc.
$61
Bayer Healthcare Pharmaceuticals Inc.
$59
ARRAY BIOPHARMA INC
$59
Regeneron Healthcare Solutions, Inc.
$52
Dova Pharmaceuticals
$52
Stemline Therapeutics Inc.
$50
Takeda Pharmaceuticals U.S.A., Inc.
$46
EISAI INC.
$45
AVEO Pharmaceuticals, Inc.
$41
Secura Bio, Inc.
$40
Boehringer Ingelheim Pharmaceuticals, Inc.
$31
AbbVie Inc.
$30
JAZZ PHARMACEUTICALS INC.
$22
Pharmacyclics LLC, an AbbVie Company
$21
Digestive Care, Inc.
$21
ADC Therapeutics America, Inc.
$21
Agios Pharmaceuticals, Inc.
$19
Genmab U.S., Inc.
$19
Deciphera Pharmaceuticals Inc.
$18
MorphoSys, US Inc.
$18
Tempus AI, Inc
$18
Geron Corporation
$18
CTI BioPharma Corp.
$17
SERVIER PHARMACEUTICALS LLC
$17
Pharmacosmos Therapeutics Inc.
$17
Aadi Bioscience, Inc.
$17
Sobi, Inc
$17
SOBI, INC
$16
Medtronic USA, Inc.
$16
Ipsen Biopharmaceuticals, Inc
$16
PUMA BIOTECHNOLOGY, INC.
$15
Clovis Oncology, Inc.
$15
AMAG Pharmaceuticals, Inc.
$15
Acrotech Biopharma Inc.
$14
Ferring Pharmaceuticals Inc.
$13
Rigel Pharmaceuticals, Inc.
$13
Fresenius Kabi USA, LLC
$13
Acrotech Biopharma LLC
$13
Advanced Accelerator Applications
$13
Foundation Medicine, Inc.
$12
Seattle Genetics, Inc.
$12
Prometheus Laboratories Inc.
$11
Top 3 companies account for 22.8% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · AUGTYRO · Alecensa · Aliqopa · BELEODAQ · BLENREP · BOSULIF · BRUKINSA · Bavencio · Blincyto · CABOMETYX · CALQUENCE · COPIKTRA · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · ENHERTU · EPKINLY · ERLEADA · Empaveli · Enhertu · Erleada · FARYDAK · FERAHEME · FIRMAGON · FOTIVDA · FOUNDATIONONE · Fyarro · GAZYVA · GILOTRIF · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kabiven · Kadcyla · LENVIMA · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LORBRENA · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Lupron Depot · MEKINIST · MONJUVI · MONOFERRIC · Nexavar · Nplate · Nubeqa · OJJAARA · ONUREG · OPDIVO · OPDUALAG · OSTEOCOOL RF ABLATION · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PYRUKYND · Padcev · Perjeta · Pertzye · Pomalyst · Proleukin · QINLOCK · REBLOZYL · ROLVEDON · RYTELO · RYZNEUTA · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TEVIMBRA · TUKYSA · Tecentriq · Tibsovo · Tivdak · Trodelvy · ULTOMIRIS · VARUBI · VEGZELMA · VENCLEXTA · VERZENIO · Venclexta · Vonjo · XALKORI · XARELTO · XOSPATA · XPOVIO · XT CDX · XTANDI · Xospata · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
20
Per 100K population
13.1
County median income
$64,499
Nearest hospital
INSPIRA MEDICAL CENTER VINELAND
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Roy is a mixed practice specialist, with above-average Medicare volume (top 8% in NJ), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Roy experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Roy performed 60,000 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Roy receive payments from pharmaceutical companies?
Yes. Dr. Roy received a total of $6,401 from 75 companies across 386 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Roy's costs compare to other hematology & oncology specialists in Vineland?
Dr. Roy's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Roy) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Vineland
Browse hematology & oncology specialists in Vineland ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NJ
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NJ
Which NJ hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology